RxDoctor Payments Data

Jose Matos, MD

Ophthalmology · San Juan, PRNPI 1295736452

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $3,000 of the $3,212 with a category attached, or 93.4%. Romark Laboratories, LC accounts for 93.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $3,013 and has fallen 97.1% since, to $86 in 2024. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,212in general payments, 2019–2025

Across 9 payments — averaging $356.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$3K
  • Rxsight Inc$70
  • AbbVie$65
  • Bausch & Lomb Americas Inc.$29
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$25
  • Novartis$24

What the payments were for

  • Food & beverage$2127%
  • Ownership interest$3,00093%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,212 in reported general payments places this provider in the 90th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$72,809
Medicare patients
257
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost267$75,588
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol220$37,823
Tobramycin-DexamethasoneTobramycin/Dexamethasone403$24,753
CombiganBrimonidine Tartrate/Timolol65$14,227
Latanoprost600$9,681
AzoptBrinzolamide20$7,495
Ketorolac Tromethamine149$6,935
Alphagan PBrimonidine Tartrate25$6,552
VyzultaLatanoprostene Bunod19$5,323
Fluorometholone74$5,027
Brimonidine Tartrate90$4,847
SimbrinzaBrinzolamide/Brimonidine Tart21$4,426
ErythromycinErythromycin Base262$4,039
Travoprost29$3,390
Prednisolone Acetate80$2,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$65$96,367357 claims
Bausch & Lomb Americas Inc.Vyzulta$29$5,32319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →